CVS Pharmacy, Inc. agreed to pay a total of $37.76 million, with $24,446,240 to the United States and the remainder to various states. The settlement resolves allegations that, from 2010 through 2020, CVS violated the False Claims Act by billing for and dispensing insulin pens to patients enrolled in government healthcare programs, including Medicare, Medicaid, TRICARE, and the Federal Employees Health Benefits Program. Specifically, CVS improperly requested and received reimbursement for premature refills, dispensed more insulin pens than patients needed per their prescriptions, and falsely under-reported the days-of-supply of insulin dispensed by its pharmacies. The VA OIG, Health and Human Services OIG, Department of Defense OIG, Office of Personnel Management OIG, and US Postal Service OIG investigated this case.
